An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation

作者: Stephanie C. Casey , Yulin Li , Dean W. Felsher

DOI: 10.1007/S12026-014-8503-6

关键词:

摘要: Tumors are genetically complex and can have a multitude of mutations. Consequently, it is surprising that the suppression single oncogene result in rapid sustained tumor regression, illustrating concept cancers often "oncogene addicted." The mechanism addiction has been presumed to be largely cell autonomous as consequence restoration normal physiological programs induce proliferative arrest, apoptosis, differentiation, and/or cellular senescence. Interestingly, recently become apparent upon inactivation, immune response critical mediating phenotypic consequences addiction. In particular, CD4(+) T cells suggested essential remodeling microenvironment, including shutdown host angiogenesis induction senescence tumor. However, adaptive innate likely involved. Thus, effectors system involved not only initiation, progression, immunosurveillance, but also regression targeted inactivation. Hence, inactivation may an effective therapeutic approach because both reverses neoplastic state within cancer reactivates remodels microenvironment.

参考文章(145)
David I. Bellovin, Bikul Das, Dean W. Felsher, Tumor Dormancy, Oncogene Addiction, Cellular Senescence, and Self-Renewal Programs Advances in Experimental Medicine and Biology. ,vol. 734, pp. 91- 107 ,(2013) , 10.1007/978-1-4614-1445-2_6
David G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, Brian K. Dallaire, Ken Wey, Ivor Royston, Thomas Davis, Ronald Levy, IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Blood. ,vol. 90, pp. 2188- 2195 ,(1997) , 10.1182/BLOOD.V90.6.2188
Lynda Chin, Alice Tam, Jason Pomerantz, Michelle Wong, Jocelyn Holash, Nabeel Bardeesy, Qiong Shen, Ronan O'Hagan, Joe Pantginis, Hao Zhou, James W. Horner, Carlos Cordon-Cardo, George D. Yancopoulos, Ronald A. DePinho#, Essential role for oncogenic Ras in tumour maintenance Nature. ,vol. 400, pp. 468- 472 ,(1999) , 10.1038/22788
Celina M. D'Cruz, Edward J. Gunther, Robert B. Boxer, Jennifer L. Hartman, Louis Sintasath, Susan E. Moody, James D. Cox, Seung I. Ha, George K. Belka, Alexander Golant, Robert D. Cardiff, Lewis A. Chodosh, c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations Nature Medicine. ,vol. 7, pp. 235- 239 ,(2001) , 10.1038/84691
Priscilla A. Furth, Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations Annals of the New York Academy of Sciences. ,vol. 1271, pp. 1- 9 ,(2012) , 10.1111/J.1749-6632.2012.06736.X
Antoni Ribas, Immunoediting the cancer genome--a new approach for personalized cancer therapy? Pigment Cell & Melanoma Research. ,vol. 25, pp. 297- 298 ,(2012) , 10.1111/J.1755-148X.2012.01001.X
Rajasekharan Somasundaram, Jessie Villanueva, Meenhard Herlyn, Intratumoral Heterogeneity as a Therapy Resistance Mechanism Advances in Pharmacology. ,vol. 65, pp. 335- 359 ,(2012) , 10.1016/B978-0-12-397927-8.00011-7
Claudia S. Huettner, Pu Zhang, Richard A. Van Etten, Daniel G. Tenen, Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genetics. ,vol. 24, pp. 57- 60 ,(2000) , 10.1038/71691
Dean W. Felsher, Cancer revoked: oncogenes as therapeutic targets Nature Reviews Cancer. ,vol. 3, pp. 375- 379 ,(2003) , 10.1038/NRC1070